Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication – Initial Safety Trial Results Find Increased Risk of Serious Heart-related Problems and Cancer with Arthritis and Ulcerative Colitis Medicine
Xeljanz, Xeljanz XR (tofacitinib): Drug Safety Communication – Initial Safety Trial Results Find Increased Risk of Serious Heart-related Problems and Cancer with Arthritis and Ulcerative Colitis Medicine
Murilo Freitas - 14:00, 3 de febrero de 2021311
0
The FDA is alerting the public that preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with the arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) compared to tumor necrosis factor (TNF) inhibitors.